Ipamorelin vs Tesamorelin: GH Secretagogues Compared

## Introduction Growth hormone (GH) secretion can be stimulated through more than one receptor pathway, and two of the most studied research compounds in this space — ipamorelin and tesamorelin — each represent a different one. Ipamorelin is a ghrelin-receptor agonist; tesamorelin is a growth hormone-releasing hormone (GHRH) analog. Both converge on the pituitary somatotroph, but they arrive there through distinct signaling routes, with different selectivity profiles, structures, and bodies of published research. This guide compares the two compounds head-to-head: how they work, what their structures look like, what the published literature reports, and which research questions each one is best suited to address. All discussion is framed around laboratory and published research; both compounds are research materials and are not approved for human or veterinary use outside their specific clinical contexts. ## Ipamorelin: The Selective Ghrelin-Receptor Agonist Ipamorelin (development code NNC 26-0161; CAS 170851-70-4) is a synthetic pentapeptide with the sequence **Aib-His-D-2-Nal-D-Phe-Lys-NH2** and a molecular weight of approximately 711.85 g/mol. It was developed at Novo Nordisk through a medicinal chemistry program that modified the growth hormone-releasing peptide (GHRP) scaffold — notably omitting the central Ala-Trp dipeptide of GHRP-1. Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a (**GHSR-1a**), the ghrelin receptor expressed in the anterior pituitary and hypothalamus. Binding triggers GH release from pituitary somatotrophs. Its defining published characteristic is selectivity. In the foundational characterization study, Raun and colleagues tested ipamorelin against a panel of pituitary and adrenal hormones in swine: while GHRP-6 and GHRP-2 increased ACTH and cortisol, ipamorelin did not release ACTH or cortisol at levels different from GHRH stimulation — even at doses more than 200-fold above the GH-releasing ED₅₀. It is frequently described as the first *selective* GH secretagogue. > **Citation:** Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. "Ipamorelin, the first selective growth hormone secretagogue." *European Journal of Endocrinology*. 1998;139(5):552-561. [PubMed PMID: 9849822](https://pubmed.ncbi.nlm.nih.gov/9849822/) Subsequent preclinical work examined ipamorelin's effects on bone biology, including longitudinal bone growth in rats. > **Citation:** Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." *Growth Hormone & IGF Research*. 1999;9(2):106-113. [PubMed PMID: 10373343](https://pubmed.ncbi.nlm.nih.gov/10373343/) Ipamorelin's GH release is short-acting and pulsatile, with GH returning to baseline within a few hours in research settings. ## Tesamorelin: The GHRH Analog Tesamorelin is a synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH), specifically modeled on GHRH(1-44) with an N-terminal modification (a trans-3-hexenoyl group) that confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation. Its molecular weight is approximately 5,136 g/mol — roughly seven times larger than ipamorelin. Rather than the ghrelin receptor, tesamorelin acts on the **GHRH receptor (GHRHR)** on anterior pituitary somatotrophs. Receptor activation raises intracellular cAMP, driving both the synthesis and the release of endogenous GH. Because it mimics the hypothalamic releasing hormone itself, tesamorelin preserves the physiologic, pulsatile pattern of GH secretion rather than overriding it. The largest published research program on tesamorelin comes from studies in HIV-associated lipodystrophy, where visceral adipose tissue accumulation was the primary endpoint. In a 26-week randomized, placebo-controlled trial of 412 patients, visceral adipose tissue decreased by 15.2% in the tesamorelin group versus a 5.0% increase with placebo, with parallel improvements in triglycerides and IGF-I levels. > **Citation:** Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. "Metabolic effects of a growth hormone-releasing factor in patients with HIV and abdominal fat accumulation: a randomized, placebo-controlled trial." *New England Journal of Medicine*. 2007;357:2359-2370. [PubMed PMID: 18057338](https://pubmed.ncbi.nlm.nih.gov/18057338/) A pooled analysis of two phase 3 trials with safety extension data confirmed reductions in visceral adipose tissue maintained through 52 weeks of continued treatment, with reaccumulation upon discontinuation. > **Citation:** Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. "Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data." *Journal of Clinical Endocrinology & Metabolism*. 2010;95(9):4291-4304. [PubMed PMID: 20554713](https://pubmed.ncbi.nlm.nih.gov/20554713/) Additional research examined tesamorelin's effects on endogenous GH pulsatility and insulin sensitivity in healthy men. > **Citation:** Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. "Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men." *Journal of Clinical Endocrinology & Metabolism*. 2011;96(1):150-158. [PubMed PMID: 20943777](https://pubmed.ncbi.nlm.nih.gov/20943777/) ## Head-to-Head Comparison | Feature | Ipamorelin | Tesamorelin | |---|---|---| | **Compound class** | Ghrelin mimetic (GHS) | GHRH analog | | **Target receptor** | GHSR-1a (ghrelin receptor) | GHRHR (GHRH receptor) | | **Structure** | Pentapeptide, ~712 Da | 44-amino-acid peptide, ~5,136 Da | | **Sequence/feature** | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | GHRH(1-44) analog, N-terminal hexenoyl modification | | **Signaling** | GHSR-1a activation on somatotrophs → GH release | cAMP-mediated GH synthesis + release | | **GH profile** | Short-acting, pulsatile | Longer-acting, preserves physiologic pulsatility | | **Selectivity note** | No significant ACTH/cortisol elevation at GH-releasing doses | Mimics endogenous GHRH signaling | | **Primary research domains** | GH-axis pharmacology, receptor selectivity, bone biology | Visceral adiposity models, lipid metabolism, GH pulsatility | | **Combination research** | Studied alongside GHRH analogs for dual-pathway synergy | Studied as a single agent in metabolic research | ## Key Differences Explained **Different receptors, different biology.** The single most important distinction is the receptor. Ipamorelin engages the ghrelin receptor (GHSR-1a) — the same receptor targeted by the endogenous stomach hormone ghrelin. Tesamorelin engages the GHRH receptor — the target of the hypothalamic releasing hormone. These are two parallel, complementary control levers on the pituitary somatotroph. **Size and complexity.** Ipamorelin is a compact pentapeptide; tesamorelin is a 44-residue peptide with a stabilizing N-terminal modification. This size difference reflects their different design goals: ipamorelin was engineered for receptor selectivity within a minimal scaffold, while tesamorelin was engineered for metabolic stability and sustained GHRH-receptor engagement. **Selectivity vs. physiologic mimicry.** Ipamorelin's research value centers on what it does *not* stimulate — ACTH, cortisol, prolactin — making it useful for isolating GH-specific effects. Tesamorelin's research value centers on mimicking endogenous GHRH signaling, preserving pulsatile GH release patterns. **Synergy in combination research.** Because the two compounds act through independent receptors, they have been studied in combination to investigate dual-pathway GH stimulation. Activating both the GHSR-1a and GHRHR pathways simultaneously produces greater GH release than either pathway alone in research models — a finding that underpins much of the comparative secretagogue literature. ## Which Is Studied for What? **Choose ipamorelin for research questions about:** - Ghrelin-receptor pharmacology and structure-activity relationships - Selective GH stimulation without cortisol/ACTH confounders - Comparative secretagogue studies (vs GHRP-6, GHRP-2, hexarelin) - Pulsatile GH-release paradigms and bone-growth models **Choose tesamorelin for research questions about:** - GHRH-receptor signaling and cAMP-mediated GH synthesis - Visceral adiposity and lipid-metabolism models - Physiologic GH pulsatility and its metabolic correlates - Long-acting GHRH analog design (DPP-4 resistance strategies) **Study both when:** - Investigating dual-pathway GH stimulation and receptor crosstalk - Comparing ghrelin-pathway vs GHRH-pathway contributions to an endpoint - Mapping the full GH-axis pharmacology landscape ## Frequently Asked Questions ### Do ipamorelin and tesamorelin work through the same receptor? No. Ipamorelin is an agonist of the ghrelin receptor (GHSR-1a); tesamorelin is an analog of GHRH that acts on the GHRH receptor (GHRHR). They are two distinct pathways that both converge on pituitary GH release. ### What is the structural difference between them? Ipamorelin is a small pentapeptide (~712 Da). Tesamorelin is a 44-amino-acid peptide (~5,136 Da) with an N-terminal modification for DPP-4 resistance. ### Why are they studied in combination? Because they activate independent receptors, combining a ghrelin-receptor agonist with a GHRH analog stimulates GH release through two complementary pathways. Research models use this pairing to investigate synergistic GH secretion. ### What is ipamorelin's selectivity advantage in research? Published characterization showed ipamorelin releases GH without significantly elevating ACTH or cortisol — unlike earlier GHRPs — even at very high multiples of the effective dose. This makes it useful for isolating GH-specific effects in experimental designs. ### What is tesamorelin best known for in the literature? The largest published research program studied tesamorelin in HIV-associated lipodystrophy, where it reduced visceral adipose tissue and improved lipid measures in randomized, placebo-controlled trials. ### Which has the larger body of clinical research? Tesamorelin has the larger published clinical program (phase 3 trials in HIV-associated lipodystrophy). Ipamorelin's literature is primarily preclinical pharmacology with early human pharmacokinetic characterization. ## Conclusion Ipamorelin and tesamorelin are complementary tools for GH-axis research, not interchangeable ones. Ipamorelin offers a compact, selective ghrelin-receptor probe for isolating GH effects; tesamorelin offers a stabilized GHRH analog for studying physiologic GH regulation and metabolic endpoints. The richest research comes from understanding them as two halves of the same regulatory system — and, where appropriate, studying them together. For researchers sourcing either compound, verify ≥99% purity by HPLC, mass spectrometry identity confirmation, and a batch-specific Certificate of Analysis from an accredited laboratory. --- **Internal link suggestions:** - Product: [Ipamorelin 10MG](/product/ipamorelin-10mg) - Product: [Tesamorelin 10MG](/product/tsm-10mg-tesa) - Related guide: [What Is Ipamorelin?](/insights/what-is-ipamorelin) - Related guide: [What Is Tesamorelin?](/insights/what-is-tesamorelin) - Related comparison: [CJC-1295 vs Ipamorelin](/insights/cjc-1295-vs-ipamorelin) For laboratory research use only. Not for human or veterinary use.